Regencell Bioscience Holdings (RGC) Debt to Equity (2020 - 2021)
Regencell Bioscience Holdings (RGC) reported Debt to Equity of -$0.11 for Q2 2021, up 90.67% on a YoY basis from -$0.06 in Q2 2020, and up 90.67% quarter-over-quarter from -$1.16 in Q2 2020.
Regencell Bioscience Holdings (RGC) Debt to Equity (2020 - 2021) Analysis & Trends
Regencell Bioscience Holdings has reported Debt to Equity for 2 years, with the latest figure at -$0.11 in Q2 2021.
- For the quarter ending Q2 2021, Debt to Equity rose 90.67% year-over-year to -$0.11; the trailing twelve-month figure through Jun 2021 stood at -$0.11 (up 90.67% YoY), and the FY2021 full-year result was -$0.11, up 90.67% from the prior year.
- Debt to Equity for Q2 2021 stood at -$0.11, up from -$1.16 in the prior quarter.
- The five-year high for Debt to Equity was -$0.11 in Q2 2021, with the low at -$1.16 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 2.02 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 2.80 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.01 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.61 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 0.86 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 0.47 |
| 10 | Regencell Bioscience Holdings | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -0.11 |
| Jun 30, 2020 | -1.16 |